MIT Technology Review's 2016 Top 50 Smartest Companies: Medical Sector Highlights and Investment Overview
MIT Technology Review annually selects the 50 “smartest” companies, based on whether their projects have created new opportunities within their respective industries. Among Chinese companies, Baidu was the highlight of this year’s full list, surging from 21st place in 2015 to 2nd in 2016. Huawei ranked 10th, Tencent 20th, and Alibaba 24th.
In the biotechnology and healthcare sectors, a total of 14 companies made the list this year, including8Family Involved in the Field of Genetics, indicating that new technologies in the field of genetics are advancing rapidly and making significant contributions to innovation.
Which medical companies are included? What is the status of their financing and investment activities?
Illumina
Project Focus: Gene Sequencing
Ranking: 3
Total Financing: $100 Million
IlluminaThe company was established in1998Year, headquartered in San Diego, California, USA, is a provider of products, technologies, and services in the field of genetic variation and biological function analysis.Shang。CompanyImprove human health by helping customers accelerate the collection, analysis, and application of biological information.In 2000, Illumina went public and is currently the world’s largest gene sequencing company. Since 2014, Illumina has been listed for three consecutive years in MIT Technology Review’s “50 Smartest Companies.”
23andME
Project Focus: Genetic Testing
Ranking: 7
Total Financing: $227 Million
23andMe, founded in 2006 and headquartered in California, USA, specializes in genetic testing products. Its distinctive feature lies in leveraging a vast database to help users identify close biological relatives based on genetic similarity, provided that the relatives’ genetic data are also included in the database. Users need only mail their saliva samples along with a payment of $99 to the company. If closely related individuals with high genetic similarity have joined the database, 23andMe will notify them, thereby facilitating reunions among long-lost siblings.
Spark Therapeutics
Project Focus: Gene Therapy
Ranking:9
Total Financing: $122 Million
Spark Therapeutics, founded in October 2013, is headquartered in Pennsylvania, USA,is a biotechnology innovation company dedicated to genetic diseases, with a focus on inherited retinal dystrophies.、Hematologic disorders and neurodegenerative diseases.At the end of last year, Spark announced that its gene therapy drug for eye disease, SPK-RPE65, had achieved very positive results in Phase III clinical trials.The company went public in June 2015.
Cellectis
Project Direction:Gene Editing
Rank: 13
Total Financing: $228 Million
CellectisFounded in 1999, it is a biotechnology company headquartered in France.。In March 2015, Cellectis launched its IPO on the Nasdaq.。In November 2015, Cellectis’s CAR-T cell line successfully saved the life of one-year-old Layla, who was suffering from leukemia.。Cellectis has already planned a formal clinical trial to test its therapy for treating leukemia using engineered immune cells. This trial could be conducted as early as this year. Immune cell therapy was listed among the 10 Breakthrough Technologies of 2016 by MIT Technology Review.。
Oxford Nanopore Technologies
Project Direction: Genetic Testing
Ranking:22
Total Financing: $379 million
Oxford Nanopore TechnologiesThe company was established inIn 2005, dedicated to the research and development of genetic testing devices.Company's ProductsMinION Sequencerwith an average read length of 5.4 kb, and some reaching up to 10 kb，Longer read lengths than those of current mainstream sequencing technologies, and this device of yoursExpanded Application Scenarios for Genetic Testing，DNA, RNA, and proteins are all targets for detection. The company's newThe compact device developed can connect to smartphones.Oxford Nanopore TechnologiesThe core technology is nanopores.
Intrexon
Project Direction: Transgenic Technology
Ranking: 31
Total Financing: $344 million
IntrexonThe company was established inIn 1998, it was a UK-headquartered company specializing in genetically modified (GM) technology research, with its headquarters located in Blacksburg, Virginia, USA. From 2013 to the present, Intrexon has been conducting research on GM mosquitoes and GM salmon, following its acquisition ofOxitecThe company’s primary project is to control dengue fever by releasing genetically modified mosquitoes. Currently, the company’s products have not yet received approval in the United States.FDA certification.
editas medicine
Project Direction: Gene Editing
Ranking: 35
Total Financing: $210 Million
Editas Medicine was founded in November 2013,Headquartered in Massachusetts, USA,is a company focused on gene editing technology, itsBy leveraging CRISPR gene-editing technology, bacteria are employed to excise harmful mutations and insert healthy DNA for disease treatment, making “bespoke” DNA a reality. EditasExpressed willingness toConducted CRISPR Gene-Editing Therapy for LCA10 in Human Clinical Trials in 2017, at which time it willUsing CRISPR gene-editing technology to directly delete a segment of the gene surrounding the variant site in the CEP290 gene. Although CRISPR gene-editing technology was invented only a few years ago,However, due to itsHighWidely welcomed by laboratories for its precision and low cost.Table of ContentsPreviously,Editas Medicine has successfully gone public.
RetroSense Therapeutics
Project Direction: Gene Therapy
Ranking: 37
Total Financing: $12 million
RetroSense TherapeuticsThe company was established in 2009., headquartered in Michigan, USA, is a company dedicated to gene therapy.In late February 2016, under the leadership of Professor Pan Zhuohua, a scientist at RetroSense Therapeutics, a Texas woman who had lost her vision due to retinitis pigmentosa (RP) received optogenetic therapy, becoming the first patient worldwide to undergo such treatment. The drug used in this therapy, RST-001, is a gene therapy agent.，Using viruses that are harmless to the human body, light-sensitive proteins from green algae are transferred into specific cells of the eye, enabling these cells to convert light signals into electrical signals and thereby substitute for the function of damaged photoreceptor cells.Currently, the company’s gene therapy drug has been approved by the U.S.FDA clearance.
veritas genetics
Project Focus: Gene Sequencing
Ranking: 40
Total Financing: Unknown
Veritas Genetics was founded in 2014 and is headquartered in Massachusetts, USA.State,Dedicated toProvide patients with whole-genome sequencing and genetic counseling services to help their physicians gain a deeper understanding of their condition.September 2015,veritas geneticsEstablish an R&D center in Hangzhou, China, to develop next-generation sequencing technologies tailored for Asian populations.After establishing its R&D center in China, the company’s first priority is research on α-thalassemia.Research on Related Genes,BecauseThis disease has a higher incidence rate among the Asian population.
seven bridges genomics
Project Focus: Genomic Data Analysis
Ranking: 42
Total Financing: $45 million
seven bridges genomics is a genomic data analysis company headquartered in Massachusetts, USACompany,Primarily provides gene sequencing research and biopharmaceutical product services.。Currently, the U.S. National Cancer Institute (NCI)’s “Cancer Genomics Cloud” and the UK NHS’s “100,000 Genomes Project” data are hosted on Seven Bridges’ cloud platform., its dataThe service facilitates cancer research for scientists worldwide. Seven Bridges Genomics has integrated cloud computing and NoSQL data technologies, such as EC2, S3, and MongoDB, into human genome sequencing and analysis. To reduce data storage costs, they also adopted Glacier. The Seven Bridges PaaS provides an interface for setting up data pipelines, which can be based on predefined models or customized according to current tasks.
T2 biosystems
Project Direction: Virus Research
Ranking:34
Total Funding: $83.5 Million
T2 biosystemsEstablished in 2006, it is a company dedicated to the research and development of pathogen detection technologies.Company,The T2Candida Panel it launched has addressed a major challenge in the diagnosis and treatment of sepsis. Last year, this diagnostic device received the Prix Galien Award for Best Biotechnology Product. T2 Biosystems has begun commercializing its pathogenic fungal detection technology, as infections caused by these fungi often lead to severe outcomes. The test takes only 3–5 hours, whereas conventional methods require 2–6 days. Currently, 16 hospitals are using T2’s equipment.
Bristol-Myers Squibb
Project Direction: Cell Therapy
Ranking: 25
Total Funding: $15.51 Million
Bristol-Myers SquibbEstablished inin 1887, headquartered inNew York, USAA science-based global diversified enterprise engaged in pharmaceuticals, healthcare, and personal care products, with its core business spanning pharmaceutical products, consumer goods, nutritional supplements, and medical devices.，Annual sales exceed $20 billion.。The immune checkpoint inhibitor drugs it produces have demonstrated remarkable efficacy in the treatment of various malignant tumors.。In October 2015, its immunotherapy drug Opdivo received the Prix Galien Award for Best Biotechnology Product. Currently, Opdivo has become a first-line treatment for metastatic melanoma and metastatic squamous non-small cell lung cancer.
Enlitic
Project Focus: Healthcare Big Data
Rank: 14
Total Funding: $15 Million
EnliticFounded in August 2014 and headquartered in San Francisco, USA, the company is dedicated to leveraging big data for medical applications.Impact ScoreAnalysis. ProjectLeveraging advanced deep learning algorithms to mine vast amounts of medical data, including medical images, diagnostic reports, and clinical trials, enables rapid, accurate, and feasible health diagnostics.，The product has been validated by radiologists in Australia,ResultsIt can effectively assist physicians in making diagnoses and formulating treatment plans.
Nestlé
Project Focus: Microbial Research
Rank: 36
Total Financing: Unknown
NestléEstablished in1866,Vevey, headquartered in Geneva, Switzerland，As the world's largest food manufacturerone of.Earlier this year, Nestlé made a surprising $120 million investment in Seres Therapeutics, announcing its entry into the currently booming field of gut microbiome research to support the development of drugs that maintain bacterial balance in the digestive tract. Nestlé will collaborate with SeresCommonR&D of Drugs Promoting Gut Health。May 2003,NestléListing.